NHS organizations across England are rejecting Palantir’s patient data technology, according to freedom of information responses revealing health bosses believe better or equal alternatives exist.
While some health bodies reported benefits from the £330m federated data platform (FDP), including improved waiting list management and surgery scheduling, numerous others have declined to use the system or reverted to previous technologies after trials.
Key Facts
- NHS trusts across England are rejecting Palantir patient data technology.
- Freedom of information responses show health bosses believe alternatives are better or equal.
- The system in question is Palantir’s £330m federated data platform (FDP).
- Trusts span from Gateshead to Truro in rejecting or reverting from the system.
- A Suffolk trust stated other systems supersede the FDP’s functionality.
The Story
Who Is Affected?
NHS organizations responsible for caring for millions of people across England are making decisions about adopting the Palantir-operated federated data platform. These range from regional trusts to larger care boards managing extensive local health services.
Some health bodies have reported positive outcomes, stating the FDP has made it easier to manage waiting lists and improved surgery scheduling. However, these benefits appear inconsistent across the system.
From Gateshead in the north to Truro in the south, NHS organizations are declining to use the platform or conducting trials before returning to legacy systems. This geographic spread suggests the rejection is not isolated to a single region or type of organization.
How Did We Get Here?
The controversy centers on the £330m federated data platform contract awarded to Palantir, a U.S.-based technology company known for its data analytics work with government agencies. The platform was designed to consolidate patient data across NHS organizations.
A Suffolk trust explicitly stated that other systems “supercede” the FDP’s functionality, suggesting technical limitations or redundancies. Greater Manchester’s care board described the Palantir system as “duplicative” and “retrograde” in their assessment.
These criticisms come through freedom of information responses, indicating that NHS organizations are being transparent about their evaluations of the technology and its effectiveness compared to alternatives they already have in place.
What Happens Next?
The mixed reception from NHS trusts raises questions about the broader rollout and evaluation of the Palantir platform. Health officials must weigh reported benefits against the concerns raised by organizations that have rejected or reverted from the system.
The feedback from freedom of information responses provides direct insight into how individual NHS organizations are assessing the value and utility of this significant investment in patient data technology.
What We Know — and What We Don’t
Verified by the source:
- NHS trusts across England are rejecting Palantir patient data technology.
- Freedom of information responses reveal health bosses see equal or better alternatives.
- Some trusts report improved waiting list management and surgery scheduling with the FDP.
- A Suffolk trust claims other systems supersede the FDP’s functionality.
- Greater Manchester care board called the system duplicative and retrograde.
Still unconfirmed:
- The total number of NHS organizations that have rejected the system.
- Specific financial implications of the rejections for NHS budgets.
- Detailed technical reasons behind the rejections beyond stated functionality concerns.
Why It Matters
A significant portion of NHS organizations are rejecting technology that represents one of the health service’s major digital investments, raising questions about effectiveness, cost-efficiency, and alignment with existing NHS workflows. This impacts taxpayer investment in public healthcare infrastructure.
What To Watch
Further freedom of information responses and official NHS communications will clarify whether these rejections represent isolated decisions or a broader pattern affecting the platform’s nationwide implementation.